文献速递认知障碍与痴呆帕金森病与运动障碍

路易体痴呆患者的认知特征与阿尔茨海默病型病理标志物

Cognitive Profile and Markers of Alzheimer Disease-Type Pathology in Patients With Lewy Body Dementias.
PubMed 文献 · Neurology · 2021-02-16

研究纳入57例路易体痴呆患者,用脑脊液生物标志物或尸检数据区分有无可能合并阿尔茨海默病型共病理,比较两组在命名、执行功能和整体认知上的表现。结果显示合并AD型共病理组在波士顿命名测验上表现更差,而执行功能和MMSE无差异;命名得分与脑脊液t-tau和p-tau呈负相关。

要点

  • 路易体痴呆合并AD型共病理者命名能力更差。
  • 执行功能与整体认知在有无AD共病理间无差异。
  • 脑脊液t-tau和p-tau与命名得分负相关。

核心结论

  • AD型共病理标志物与路易体痴呆患者的语言表现受损相关。
  • 基于生物学的分类可能优于临床综合征分类以解释临床异质性。

研究设计与样本

  • 研究纳入57例路易体痴呆患者(DLB 38例,PDD 19例),均有AD脑脊液生物标志物和神经心理数据。
  • 用尸检验证的脑脊液切点(t-tau:Aβ42比值>0.3,n=43)或尸检数据(n=14)将患者分为LBD+AD组(n=26)和LBD-AD组(n=31)。
  • 采用协方差分析比较两组及临床表型(DLB、PDD)在命名、执行功能和整体认知上的差异,并调整协变量。

主要发现

  • LBD+AD组在30项波士顿命名测验(BNT)上得分低于LBD-AD组(F=4.80,p=0.03)。
  • 两组在字母流畅性、倒背数字广度和MMSE上表现相似(均p>0.1)。
  • 临床定义的PDD和DLB组在任何这些测量上均无差异(均p>0.05)。
  • 所有患者中,BNT得分与脑脊液t-tau(ρ=-0.28,p<0.05)和p-tau(ρ=-0.26,p=0.05)呈负相关,与Aβ42无关(p>0.1)。

关键数值与推荐

  • 脑脊液t-tau:Aβ42比值>0.3作为尸检验证的切点用于分类可能AD型共病理。
  • 命名评估采用30项波士顿命名测验(BNT)。
  • 执行功能评估采用字母流畅性(LF)和倒背数字广度(RDS)。
  • 整体认知评估采用简易精神状态检查(MMSE)。

临床怎么用

  • 对路易体痴呆患者进行命名评估有助于识别可能合并AD型共病理者。
  • 脑脊液t-tau和p-tau水平升高可能提示语言表现更差。
  • 基于生物标志物的分类可能比临床综合征分类更能反映认知异质性。

局限性

  • 样本量较小(57例),部分分类依赖脑脊液切点而非全部尸检确认。
  • 横断面设计无法推断因果关系。
  • 未报告其他潜在混杂因素的控制情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether patients with Lewy body dementia (LBD) with likely Alzheimer disease (AD)-type copathology are more impaired on confrontation naming than those without likely AD-type copathology. METHODS: We selected 57 patients with LBD (dementia with Lewy bodies [DLB], n = 38; Parkinson disease dementia [PDD], n = 19) with available AD CSF biomarkers and neuropsychological data. CSF β-amyloid1-42 (Aβ42), phosphorylated-tau (p-tau), and total-tau (t-tau) concentrations were measured. We used an autopsy-validated CSF cut point (t-tau:Aβ42 ratio > 0.3, n = 43), or autopsy data when available (n = 14), to categorize patients as having LBD with (LBD + AD, n = 26) and without (LBD - AD, n = 31) likely AD-type copathology. Analysis of covariance tested between-group comparisons across biologically defined groups (LBD + AD, LBD - AD) and clinical phenotypes (DLB, PDD) on confrontation naming (30-item Boston Naming Test [BNT]), executive abilities (letter fluency [LF], reverse digit span [RDS]), and global cognition (Mini-Mental State Examination [MMSE]), with adjustment for age at dementia onset, time from dementia onset to test date, and time from CSF to test date. Spearman correlation related cognitive performance to CSF analytes. RESULTS: Patients with LBD + AD performed worse on BNT than patients with LBD - AD (F = 4.80, p = 0.03); both groups performed similarly on LF, RDS, and MMSE (all p > 0.1). Clinically defined PDD and DLB groups did not differ in performance on any of these measures (all p > 0.05). A correlation across all patients showed that BNT score was negatively associated with CSF t-tau (ρ = -0.28, p < 0.05) and p-tau (ρ = -0.26, p = 0.05) but not Aβ42 (p > 0.1). CONCLUSION: Markers of AD-type copathology are implicated in impaired language performance in LBD. Biologically based classification of LBD may be advantageous over clinically defined syndromes to elucidate clinical heterogeneity.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Howard E, Irwin DJ, Rascovsky K, et al. Cognitive Profile and Markers of Alzheimer Disease-Type Pathology in Patients With Lewy Body Dementias. Neurology. 2021. PMID: 33593865. doi:10.1212/WNL.0000000000011699

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。